Lentiviral Vector Resource
Lentiviral overexpression vector construction is a design-to-validation process in which promoter choice, transgene architecture, regulatory elements, and selection strategy determine stable expression and experimental reliability. A robust workflow connects gene-of-interest and tag design with LTR, cPPT, WPRE, and other vector elements, followed by cloning, sequence verification, packaging, titration, transduction, and expression testing. Matching the construct to the target cell and expression goal helps generate reliable stable cell lines and reproducible gain-of-function models through lentiviral vector development, tissue-specific promoter regulation, and lentiviral vector titration.
Construction Workflow
The process moves from defining the target transcript through cloning, packaging, and finally validation in transduced cells. Front-end design determines everything downstream.
Select the correct isoform and coding sequence (CDS) for your gene of interest.
Choose promoter, tag, fluorescent marker, and selection marker against your assay goals.
Clone the insert and confirm the full sequence by Sanger or whole-plasmid sequencing.
Co-transfect with packaging plasmids, concentrate, and determine functional titer.
Infect target cells, select stable pools, and confirm expression and function.
Promoter Selection
For stable overexpression, compare promoter activity in the actual target cell at an early readout and after the intended number of passages. The apparent strength and persistence of CMV, CAG, EF1α, PGK, or a lineage-restricted promoter can shift with cell state and differentiation, so choose from measured expression and assay tolerance rather than a fixed strength ranking.
| Promoter | Strength | Silencing Risk | Best Use |
|---|---|---|---|
| CMV | High | Higher in stem cells / long-term culture | Useful to screen for strong early expression; test persistence in stem or differentiating cells before choosing it for stable models |
| CAG | Very high | Low–moderate | Useful when broad expression is needed; account for promoter length and test whether the resulting protein level is tolerated |
| EF1α | Moderate | Low | Candidate for sustained expression in selected stem, primary, or blood cell models; confirm behavior after selection and passage |
| PGK | Moderate | Low | Candidate when moderate expression is preferred; verify that the measured level still reaches the intended functional threshold |
| Tissue-specific | Variable | Context-dependent | Candidate for cell-class restriction; test leakage and expression strength in the exact target culture or differentiated model |
For cell-restricted expression, explore tissue-specific promoter-regulated lentiviral vectors.
Vector Elements
A transfer-vector map should separate the elements required for vector RNA production and packaging from those that shape transgene expression after integration. Verify each sequence and orientation, then assess both production yield and target-cell expression because a high particle count does not by itself establish a useful overexpression model.
The LTR architecture supports production of transfer-vector RNA and the integrated provirus. A self-inactivating 3' LTR reduces LTR promoter activity after reverse transcription, so the internal promoter becomes central to expression and its interaction with neighboring sequences should be evaluated.
The Ψ region is required for efficient recognition and encapsidation of transfer-vector RNA. Confirm that cloning has not disrupted this region, especially when redesigning the 5' portion of a backbone or inserting a large expression cassette.
The RRE works with Rev supplied during production to export unspliced vector RNA for particle assembly. Its effect depends on backbone context, so preserve the validated element and check vector yield if the surrounding architecture is changed.
The cPPT/CTS region contributes to the central DNA flap formed during reverse transcription and can improve transduction in some settings. Evaluate its contribution in the selected backbone and target cells rather than treating it as a substitute for functional titration.
WPRE can increase transgene RNA accumulation and expression, but the gain varies with promoter, cell type, and construct design. Specify the WPRE variant in the vector map and compare expression using the same integration or dose context.
The Kozak context affects translation initiation around the start codon. T2A or P2A allows two proteins to be produced from one transcript, but junction design and cleavage efficiency should be checked when a marker or second payload is included.
Design Considerations
Calculate the total transfer-vector RNA length and decide which modules are essential to the assay. The promoter, ORF, tag, marker, and regulatory elements affect expression and manufacturing differently; compare construct size, functional titer, and protein readout before choosing the final architecture.
Choose a validated SIN architecture: the 3' LTR deletion reduces LTR promoter activity in the integrated construct, while separated packaging functions reduce opportunities for recombination. Document the transfer and helper plasmid configuration and use appropriate lot-level safety testing for the intended study.
Budget the full packaged genome: count the promoter, ORF, marker, and regulatory elements as well as the backbone sequences that remain in vector RNA. Larger genomes can reduce functional yield, but the effect is construct-dependent; compare candidate designs experimentally.
Match the tag to the readout: a separate reporter or untagged ORF may be preferable when native protein behavior is critical. If a fusion is needed for imaging or purification, test both tag orientation and biological activity against a suitable control.
Compare co-expression formats: a 2A peptide can keep the cassette compact, while IRES-based designs can produce a different downstream expression ratio. Measure each protein separately and verify 2A cleavage or IRES-driven expression before relying on a fluorescent marker as a proxy for the payload.
Control timing for sensitive payloads: inducible expression can separate cell-line establishment from activation of a toxic or dose-dependent transgene. Evaluate basal leak, induction range, reversibility, and the effect of the inducer in the target cells; explore inducible lentiviral vector systems.
From Question to Evidence
Creative Biolabs can design, construct, optimize, and package your lentiviral overexpression vector end-to-end, delivering high-titer particles ready for stable transduction.
Define the intended isoform, target cell, expression level, and readout before selecting promoter, tag, and marker modules. Build the transfer construct and verify the ORF, junctions, orientation, and relevant backbone elements so the packaged vector matches the study design.
Compare promoter and regulatory-element configurations for the desired balance of protein output, persistence, and cell fitness. Use codon or cassette changes only when appropriate for the payload, and recheck sequence, functional titer, and expression after each design revision.
Package the verified construct with the selected helper system, then concentrate and characterize the lot for the planned cell model. Report genome or physical measures alongside a cell-based functional titer where relevant, so particle quantity can be interpreted with transduction performance.
Design Tet-based or other inducible architectures around the required activation window and expression range. Check basal expression before induction, dose response after induction, and reversibility over the intended experiment, particularly for toxic or growth-altering payloads.
Review ready-made recombinant lentivirus when the available isoform, promoter, marker, and tag match the intended assay. Confirm the product sequence, lot-level titer, and target-cell compatibility before using a catalog reagent as the basis for a stable line or gain-of-function comparison.
Selected Reading
Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73(4):2886-2892. https://doi.org/10.1128/JVI.73.4.2886-2892.1999.
Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 2000;101(2):173-185. https://doi.org/10.1016/S0092-8674(00)80828-4.
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. https://doi.org/10.1128/JVI.72.11.8463-8471.1998.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
